Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Delcath Systems logo — Delcath Systems, Inc. is an interventional oncology company...

Delcath Systems

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of metastatic liver cancer.

Founded 1987 United States New York, United States 86 employees Post Ipo Equity Total: $276.60M Biotechnology, Health Care +1

General Information

Company Name Delcath Systems
Founded Year 1987
Location United States New York, United States +3
Founders / Decision Makers
Team member Team member Team member
Employees 86
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Delcath Systems moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Delcath Systems

Delcath Systems, Inc. is an interventional oncology company with a focus on treating metastatic liver cancer. The company, listed on NASDAQ under the ticker symbol DCTH, specializes in the treatment of primary and metastatic liver cancers. Its proprietary product, Melphalan Hydrochloride for Injection, utilized with the Delcath Hepatic Delivery System (Melphalan/HDS), is designed for high-dose chemotherapy administration to the liver while controlling systemic exposure. Delcath is currently in late-stage clinical development in the United States, while already conducting commercial activities in Europe. In Europe, its product is marketed as the Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), a CE Marked device. The commercial strategy for CHEMOSAT revolves around growing clinical adoption in major European markets and leveraging physician experience to support appeals for reimbursement. To date, over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, Delcath launched the FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma and has ongoing investigations in orphan indications related to hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The company believes Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy. Delcath Systems, Inc. was founded in 1987 and is headquartered in the United States. The most recent investment in the company totaled $7.00M and was in the form of a Post-IPO Equity investment on 15 March 2024.

Taxonomy: Interventional Oncology, Metastatic Liver Cancer, Medical Device, High-dose Chemotherapy, Clinical Development, Melphalan/HDS, CE Marked Device, European Market, FOCUS Pivotal Study, Hepatic Dominant Ocular Melanoma, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Directed Therapy, Drug Delivery, Specialty Pharmaceutical

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 15 Mar 2024
Post-IPO Equity •••••• - 01 Sep 2023
Post-IPO Equity •••••• 5
Investor Investor
•••• •••• 		27 Mar 2023
Post-IPO Equity •••••• - 08 Dec 2022
Post-IPO Equity •••••• - 18 Jul 2022

View All 13 Funding Rounds

Delcath Systems Alternatives & Competitors

Delcath Systems vs
Vital Therapies
Vital Therapies

Pioneering the future of liver therapy with innovative cell-based treatments for acute liver failure...

Private Equity
Biotechnology, Health Care
Compare Delcath Systems vs Vital Therapies
Delcath Systems vs
ENDRA Life Sciences (Nasdaq: NDRA)
ENDRA Life Sciences (Nasdaq: NDRA) United States

Focused on early detection of liver disease

Post Ipo Equity
25 employees
Biotechnology, Health Care
Compare Delcath Systems vs ENDRA Life Sciences (Nasdaq: NDRA)
Delcath Systems vs
Barcelona Liver Bioservices
Barcelona Liver Bioservices Spain

BLB aims to provide superior-quality research services and consulting in the field of Hepatology

3 employees
Health Care, Marketing
Also compare with: Delcath Systems vs Ark Clinical Research Ark Clinical Research

FAQ About Delcath Systems

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of metastatic liver cancer.
Delcath Systems was founded in 1987.
Delcath Systems is headquartered in New York, United States.
Delcath Systems operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Delcath Systems has approximately 86 employees.
Delcath Systems has completed 13 funding rounds, raising a total of $276.60M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Delcath Systems include Vital Therapies, ENDRA Life Sciences (Nasdaq: NDRA), Barcelona Liver Bioservices, Ark Clinical Research, Avenu Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Delcath Systems and Vital Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Delcath Systems and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy